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INTRODUCTION                                           
                
Carcinoma afflicts all the communities worldwide. Breast carcinoma is a major health concern 
and a leading cause of death among women.1 It causes 3, 76,000 deaths in a year worldwide and every 
year 9, 00,000 new cases are diagnosed4. Among  the Indian women carcinoma of  the breast and 
cervix account  for 60% of total  cases,  of which  breast  carcinoma accounts for 10.4%  1.  A study 
conducted by WHO revealed that Chennai has the highest incidence among all leading centres in India 
accounting for  26/1, 00,000 women 7. The mean age of occurrence is 42  years.3, 4
The approach to the management of  breast carcinoma has undergone enormous changes over 
the last 20 years 13. Today, the choice of conservative and reconstructive surgery is more popular than 
mastectomy. Such changes are accompanied by increasing range of systemic, hormonal and cytotoxic 
drugs  used  in  both  adjuvant  and  neoadjuvant  settings  6,  13. Prognosis  and  management  of  breast 
carcinoma are  influenced by the classic  variables  such as  histological  type and grade,  tumor size, 
lymph node status, Estrogen, Progesterone receptor status and HER-2/neu overexpression .11
Identification  of  biomarkers  plays  a  paramount  role  in  the  treatment,  management   and 
prognosis of breast carcinoma.  Determination of hormonal status is an important primary assessment 
at the time of diagnosis of breast carcinoma. Testing for Estrogen and Progesterone receptor status is 
critical to plan optimal treatment for breast cancer.1, 2
     Estrogen  receptor  is  a  well  established  predictive  and  prognostic  factor  in  breast  cancer. 
Patients  with  ER-positive/PR-positive  tumors  have  a  better  prognosis  than  patients  with  ER-
negative/PR-negative tumors. Hormone receptor test is done routinely in these cases since hormone 
treatment has fewer side effects and it prevents recurrence in 25% of cases.1
HER2/neu status became clinically relevant with the demonstration that          HER-2/neu 
positive tumors have a worse prognosis than HER2/neu negative tumors.2 It has been recognised that 
HER2/neu overexpression served as both a marker of aggressive disease and a target for treatment. 
HER2/neu  status  not  only  predicts  poor  outcome,  but  predicts  sensitivity  to  treatment  with 
Trastuzumab (Herceptin), a humanized monoclonal anti- HER2/neu antibody .13, 14
With these prognostic implications, the need for accurate and precise assessment of ER, PR, and 
HER2/neu expression in breast carcinoma is critical in the determination of patients appropriate for 
treatment  with  these  drugs.  Immunochemistry  is  an  important  tool  in  precise  histopathological 
diagnosis. Immunohistochemistry (IHC) is the most commonly used method of testing for ER, PR, and 
HER2/neu status.2 
                            Survival and response to hormone therapy are most favourable among women  who are receptor 
positive,  intermediate  for  tumors  discordant  on  receptor  status  and  least  favourable  for  receptor 
negative patients.  The interrelationship of   Estrogen,  Progesterone receptor  status and HER-2/neu 
overexpression  has  an important  role  in  management  of  breast  carcinoma.  It  has  been shown that 
patients with HER-2/neu overexpression do not respond to tamoxifen therapy, while they serve as a 
candidates for trastuzumab therapy.3, 15, 18
AIM OF THE STUDY
1. To statistically evaluate the occurrence of breast lesions in  patients attending Comibatore 
Medical College hospital.
2. To evaluate the distribution of Estrogen, Progesterone receptors and     HER-2/neu in breast 
malignancies by using immunohistochemical method.
3. To correlate the receptor expression in various histological types of breast carcinoma. 
4. To find out the correlation of Estrogen, Progesterone receptors and      HER-2/neu status 
with other possible variables. 
                                   REVIEW OF LITERATURE
INCIDENCE AND EPIDEMIOLOGY
Carcinoma  afflicts  all  the  communities  worldwide.  Approximately  10  million  people  are 
diagnosed  with  carcinoma and  more  than  6  million  people  die  of  the  disease  every year.4 Breast 
carcinoma is the most common non-skin malignancy in women. It causes 3, 76,000 deaths in a year 
worldwide and every year 9, 00,000 new cases are diagnosed. 5, 6
Among the Indian women cancer cervix and breast carcinoma accounts for 60% of total cases, 
of which breast  carcinoma incidence is  10.4%. A study conducted by WHO 7 (1999) denotes that 
Chennai accounts for the highest incidence among all the  leading centres in India (ie) 26/1, 00,000 
women. The mean age of occurrence is 42 years. 4, 6
         There has been a sharp increase in the detection of breast carcinoma, owing to the widespread use 
of mammography.  3, 7 However the mortality from breast carcinoma is beginning to fall, presumably 
because of  earlier diagnosis and improved therapy.13
RISK FACTORS
The frequency of the disease has prompted an intensive study of risk factors. It has been proposed 
that the common denominator for most of these factors is strong and prolonged estrogen stimulation 
operating in a genetically susceptible background.   4, 6,9,10,11
1. Country  of  birth:  Incidence  of  breast  carcinoma  is  more  in  developed  countries  than  in 
developing countries.
     2. Family history: Women who have first degree relatives with breast carcinoma have a risk two to 
three times that of the general population.
3. Menstrual  and  reproductive  history:  Increased  risk  is  correlated  with  early  menarche, 
nulliparity, age at first birth and late menopause owing to hyper estrogenic stimulation 9,10
4. Breast biopsies: Increased risk is associated with prior biopsies showing atypical hyperplasia.
5. Race and socio economic group:  Incidence of breast carcinoma is high among  
      the high socio- economic group.  The risk of developing invasive carcinoma  
      within the  next 20 years at age 50 is 1 in 26 for Asian / Pacific islanders.11
     Additional risk factors as follows are also recognized, but there is a lack of definitive correlation. 4, 
6,7, 9,10 
1. Estrogen exposure: Post menopausal hormone replacement therapy and use of  oral contraceptive 
drugs are associated with increased risk of breast cancer.  Oophorectomy reduces the risk of breast 
carcinoma by 75%.
2. Radiation exposure: Those who are exposed to therapeutic radiation and atom 
bomb survivors have a high incidence of breast cancer.
3. Carcinoma of contralateral breast and endometrium: Increased risk is associated 
with the above mentioned factors. 
4. Geographic influence: Breast cancer incidence rates are increased about four times in the United 
States and Europe than in other countries.
 5.   Diet: High fat diet and obesity carry increased risk.
6. Exercise: Reduced risk is associated with premenopausal women who 
    exercise regularly.
7. Breast feeding: The longer the women breast feed their children the greater is the     
    reduction in the risk of breast carcinoma.
ETIOLOGY AND PATHOGENESIS  9,10 
             The major risk factors for the development of breast carcinoma are hormonal and genetic 
(family history). Breast carcinoma can therefore be divided into                1) Sporadic breast carcinoma. 
2) Hereditary breast carcinoma. 
HEREDITARY BREAST CARCINOMA:
          
             About 25% familial cancers can be attributed to two highly penetrant autosomal dominant 
genes BRCA1, and BRCA2, located in 17q21 and 13q12.3 respectively.  BRCA1 and BRCA2 do not 
show  sequence  homology.  They  function  on   similar  pathways  and  interact  with  multiprotein 
complexes. Both act as tumour suppressor genes that confers the risk of malignancy.  Loss of these 
function  leads  to  breast  carcinoma  perhaps  due  to  intermittent  proliferation  of  breast  epithelium. 
BRCA1 interacts  with  Estrogen  receptor  and  is  involved  in  X-  Chromosome  activation.  BRCA1 
associated breast cancers are most common in medullary carcinoma (67%) and mucinous carcinoma 
(55%), BRCA2 mutation does not have a distinct morphologic appearance. 12, 13, 17
SPORADIC BREAST CARCINOMA: 
              The major risk factors for sporadic breast cancer are related to hormone exposure, gender, age 
at  menarche  and menopause,  reproductive  history and exogenous estrogens.  These  carcinomas are 
associated with post menopausal women and they overexpresses the estrogen receptor. 10,12
WHO HISTOLOGICAL CLASSIFICATION OF TUMOURS OF THE BREAST 17 
Epithelial tumours 
Invasive ductal carcinoma, not otherwise specified
Mixed type carcinoma
Pleomorphic carcinoma
Carcinoma with osteoclastic giant cells 
Carcinoma with choriocarcinomatous features 
Carcinoma with melanotic features
Invasive lobular carcinoma
Tubular carcinoma
Invasive cribriform carcinoma
Medullary carcinoma
Mucinous carcinoma and other tumours with abundant mucin
Mucinous carcinoma
Cystadenocarcinoma and columnar cell mucinous carcinoma
Signet ring cell carcinoma
Neuroendocrine tumours
Solid neuroendocrine carcinoma
Atypical carcinoid tumour
Small Cell/oat cell carcinoma
Large cell neuroendocrine carcinoma
Invasive papillary carcinoma
Invasive micropapillary carcinoma
Apocrine carcinoma
Metaplastic carcinomas
     Pure epithelial metaplastic carcinomas
Squamous cell carcinoma
Adenocarcinoma with spindle cell metaplasia
Adenosquamous carcinoma
Mucoepidermoid carcinoma
    Mixed epithelial/mesenchymal metaplastic carcinomas
Lipid-rich carcinoma
Secretory carcinoma
Oncocytic carcinoma
Adenoid cystic carcinoma
Acinic cell carcinoma
Glycogen-rich clear cell carcinoma
Sebaceous carcinoma
Inflammatory carcinoma
Lobular neoplasia
Lobular carcinoma in situ
Intraductal proliferative lesions 
Usual ductal hyperplasia
Flat epithelial atypia
Atypical ductal hyperplasia
Ductal carcinoma in situ
Microinvasive carcinoma
Intraductal papillary neoplasms
Central papilloma
Peripheral papilloma
Atypical papilloma
Intraductal papillary carcinoma
Intracystic papillary carcinoma
Benign epithelial proliferations
     Adenosis including variants
Sclerosing adenosis
Apocrine adenosis
 Blunt duct adenosis
Microglandular adenosis
Adenomyoepithelial adenosis
   Radial scar / complex sclerosing lesion 
   Adenomas 
Tubular adenoma
Lactating adenoma 
Apocrine adenoma
Pleomorphic adenoma
Ductal adenoma
Myoepithelial lesions
Myoepitheliosis
Adenomyoepithelial adenosis
Adenomyoepithelioma
Malignant myoepithelioma
Mesenchymal tumours
Haemangioma
Angiomatosis
Haemangiopericytoma
Pseudoangiomatous stromal hyperplasia
Myofibroblastoma
Fibromatosis (aggressive)
Inflammatory myofibroblastic tumour
Lipoma
Angiolipoma
Granular cell tumour
Neurofibroma
Schwannoma
Angiosarcoma
Liposarcoma
Rhabdomyosarcoma
Osteosarcoma
Leiomyoma
Leiomyosarcoma
Fibroepithelial tumours
Fibroadenoma
Phyllodes tumour
      Benign
      Borderline
      Malignant
Periductal stromal sarcoma, low grade
Mammary hamartoma
Tumours of the nipple 
Nipple adenoma
Syringomatous adenoma
Paget disease of the nipple 
Malignant lymphoma
Diffuse large B-cell lymphoma
Burkitt lymphoma
Extranodal marginal-zone B-cell lymphoma of MALT type
Follicular lymphoma 
Metastatic tumours
Tumours of the male breast 
Gynaecomastia
Carcinoma
Invasive
In situ 
MICROSCOPIC TYPES OF BREAST CARCINOMA:
The two key determinations  to  make in  the  morphologic  study of  breast  carcinoma are  1) 
whether the tumour is confined to the epithelial component of the organ (in situ carcinoma) or has 
invaded into the stroma (invasive carcinoma). 
2) whether it is ductal or lobular type. 14,15,16
INVASIVE CARCINOMA:
              Tumours included in this category are all those in which stromal invasion is detectable, 
whether an insitu component is identifiable or not. Invasive tumours can be divided into two major 
categories:  ductal type and lobular type. 14, 15
INVASIVE DUCTAL CARCINOMA –NOS TYPE:
           Rosen (1975)  18 accounts that this type constitutes 65-80% of mammary carcinomas. WHO 
classification of Invasive ductal carcinoma -NOS type tumour is one of exclusion: “Invasive ductal 
carcinoma is most frequently encountered malignant tumour, not falling into any other categories of 
invasive mammary carcinoma”.17
Microscopically  WHO classification  requires  a  non-specialized  pattern  in  over  50% of  the 
tumour area to be classified as NOS- type. Typically combinations of infiltrative margins, trabecular, 
diffuse sheet like, acinar and nested patterns are noted.  Histological grading of the tumour depends on 
tubular  formation,  pleomorphism  and  mitotic  count.  They  are  graded  into  well  differentiated, 
moderately differentiated and poorly differentiated grades. 14, 15
Predictive  value  of  Estrogen  receptor  is  evaluated  by  quantitative  immunohistochemical 
analysis in breast carcinoma.19,23  Hormone receptor studies of IDC-NOS type shows  70-80% Estrogen, 
Progesterone positivity and 15-30%            HER-2 / neu positivity 14,15,16. 
INVASIVE LOBULAR CARCINOMA: (ILC)
           Foote and Stewart (1946)  20 introduced the term Infiltrating Lobular carcinoma. Tavassoli 
(1992) 21 described that ILC of breast composed of small cells with linear growth pattern. Over 90% of 
the carcinoma should have a lobular morphology to be classified in this group. This type represents 
4.9-15% of all invasive breast carcinomas. 22 
 
          There is some evidence that increased risk of lobular carcinoma occur in postmenopausal women 
and it is frequently multicentric when compared with  other sub-types. 16,22
               Microscopically the cell type characteristic of invasive lobular carcinoma is non-cohesive 
with  relatively round or  oval  eccentrically placed nuclei  with  small  nucleoli  and small  amount  of 
cytoplasm. The classical pattern of single file and targetoid arrangements were noted.  14,17 
      
        Dixan J M (1985)  22  conducted receptor assay that reveals Estrogen,  Progesterone receptor 
positivity in 67 -92% of cases, 14,15  E-Cadherin negative 15 and HER-2/neu negativity. 21
MUCINOUS CARCINOMA:  
In 1852 Robinson RR has described about gelatinous carcinoma of breast. The incidence ranges 
from 0.8 -6% probably reflecting the applied diagnostic criteria.17 The tumor type is characterized by a 
mucinous morphology in over 90% of the tumour.  WHO classification describes “large amount of 
extracellular mucin sufficient to be visible both grossly and microscopically surrounding the tumour 
cells”. 17
Diab  SG  (1999)  26  in  his  study  concluded  Estrogen  receptor  positivity  in       73-95%, 
progesterone receptor positivity 79-84% and HER-2/neu negativity of mucinous carcinoma.  
Mucinous carcinoma tends to be negative for HER-2/neu and for EGFR 24,25 
MEDULLARY CARCINOMA:
Geschicker  C  F  (1945)  described  about  high  grade  tumor  as  a  different  entity  in  breast 
carcinoma. Grossly the tumor appears as a well circumscribed mass and soft in consistency. 14 WHO 
defined as “well circumscribed carcinoma composed of poorly differentiated cells with scant stroma 
and prominent lymphocytic infiltration”.  Despite the high grade of  tumor it carries relatively good 
prognosis. 17
Immunohistochemical studies of Estrogen expression are found to be negative 14,27,28  and they 
also exhibit characteristic immunophenotype (i.e) p53 positive,    HER-2 / neu negative 27
NEUROENDOCRINE CARCINOMA;
In 1975 Coombes RC has described neuroendocrine carcinoma in his study. In 1977 Cubilla AL 
et  al  30 described  primary  carcinoid  tumor  of  breast  in  eight  patients.  WHO defines  this  type  of 
carcinoma with neuroendocrine marker positivity noted in more than 50% of the cell population. 17  A 
study confirmed that  10-18% breast  carcinoma showed evidence of  neuroendocrine differentiation. 
This type has an infiltrative morphology with component cells arranged in nests, sheets or trabecular 
formation and peripheral palisading of cell groups. 14,15,17
Immunohistochemical studies by LeeAK31 show neuroendocrine marker positivity in 82% of 
the cases. However 67% show Estrogen receptor positivity and 56% exhibits Progesterone receptor 
positivity. 30, 32  
HER-2/neu overexpression is found to be negative in this type of tumour 32 
PAPILLARY CARCINOMA: 
Foote  and  Stewart  20 (1946)  defined  it  as  “A  rare  carcinoma  whose  invasive  pattern 
predominantly is in the form of papillary structures.” 
Estrogen, Progesterone receptor positivity and HER-2/neu negativity are characteristic of this 
tumour. 31,33
Zekiglu.O.ErhanY  et  al  (2004)34 conducted  immunohistochemical  analysis  of  papillary 
carcinoma and interpreted receptor positivity in upto 89% of cases and HER-2/neu in 27 % of cases. 
33,34
CARCINOMA WITH METAPLASIA:
              In  1984  Kaufman  M.W  35 described  special  edition  of  mammary  carcinoma  with 
pseudosarcomatous  metaplasia.  WHO  (2003)  publication  defines  metaplastic  carcinoma  breast  as  “a 
heterogeneous group of neoplasm with spindle cells, squamous cells or with mesenchymal differentiation” 
17.
 Oberman  HA (1987)  36  et  al  found hormone  receptors  and  HER-2/neu found to  be  negative. 
Wargotz ES et al (1989) 37   showed they are positive for keratin, EMA and S100 15.
PROGNOSTIC AND PREDICTIVE FACTORS 9,10,12,17
            Prognosis is determined by the pathologic examination of the primary carcinoma and the 
axillary  lymph  nodes.  Major  prognostic  factors  are  the  strongest  predictors  of  death  from breast 
carcinoma and are incorporated into the American Joint committee cancer (AJCC) staging system. 
Predictive factors are used to determine the likelihood of response to a particular therapy. 12
1. Invasive carcinoma or in situ disease:
     By definition, in situ carcinoma is confined to the ductal system and cannot metastasize. In 
contrast, at least half of invasive carcinomas will have metastasized locally or distantly at the time of 
diagnosis. 15
2. Distant metastases:
 Once  distant  metastases  are  present,  cure  is  unlikely,  although  long-  term remissions  and 
palliation can be achieved, especially for women with hormonally responsive tumors. Favoured sites 
for dissemination are the lungs, bones, liver, adrenals, brain and meninges. 6,13 
3. Lymph node metastases:
   Axillary lymph node status is the most important prognostic factor for invasive carcinoma in 
the absence of distant metastases. The sentinel node is highly predictive of the status of the remaining 
nodes.  Sentinel  node biopsy can spare women the increased morbidity associated with a complete 
axillary dissection. Macrometastases (>0.2 cm) are of proven to be prognostic importance. 9,15 
4. Tumor size:
            The size of the carcinoma is the second most important prognostic factor and is independent 
from lymph node status. 16 
5. Locally advanced disease: 
Tumors invading into skin or skeletal muscle are frequently associated with concurrent distant 
disease. 13
6. Inflammatory carcinoma:
Women presenting with the clinical appearance of breast swelling and skin thickening have a 
particularly poor prognosis. 3 
MINOR PROGNOSTIC FACTORS:
In this group, minor prognostic factors can be used to decide among chemotherapy regimens 
and/or  hormonal  therapies.  Three  of  these  factors  estrogen  receptor,  progesterone  receptor,  and 
HER2/neu-are most useful as predictive factors for response to specific therapeutic agents. 13,18 
1. Histologic subtypes:
The  30-year  survival  rate  of  women  with  special  types  of  invasive  carcinomas  (tubular, 
mucinous, medullary,  lobular, and papillary) is greater than 60% compared with less than 20% for 
women with cancers of no special type. 18
2. Tumor grade: 
The most commonly used grading system to assess the degree of tumor differentiation (Scraff 
Bloom Richardson) combines nuclear grade, tubule formation, and mitotic rate.
3. Estrogen and Progesterone Receptors:
Current assays use immunohistochemistry to detect the receptor status in the nucleus. 19 Women 
with hormone receptor-positive cancers have a slightly better prognosis than do women with hormone 
receptor-negative  carcinomas.  The  evaluation  of  hormone  receptors  is  most  valuable  to  predict 
response to therapy. 39
4. HER-2/neu:
HER2 (human epidermal growth factor receptor 2) or c-erb B2 is a transmembrane glycoprotein 
involved in cell  growth control.  HER2/neu is  overexpressed in 20% to 30% of breast  carcinomas. 
Overexpression  of  HER-2/neu  is  associated  with  a  poor  prognosis.  Transtuzumab  is  a  humanized 
monoclonal antibody to HER-2/neu developed to specifically target tumor cells and it is hoped to spare 
normal cells. 24
5. Lymphovascular invasion (LVI):
Tumor cells may be seen within vascular spaces (either in lymphatic or in small capillaries 
surrounding tumours). This finding is strongly associated with the presence of lymph node metastasis 
and is a poor prognostic factor. 38 
6. Proliferative rate:
Proliferation  can  be  measured  by  flow  cytometry  (as  the  S-phase  fraction),  by  thymidine 
labelling  index,  by  mitotic  counts,  or  by  immunohistochemical  detection  of  cellular  proteins 
(e.g.,cyclins, Ki-67) produced during the cell cycle. Tumours with high proliferation rates have the 
worst prognosis. 12
7. DNA content:
The amount of DNA per tumour cell  can be determined by flow cytometric analysis  or by 
image analysis of tissue sections. Aneuploid tumours are those with abnormal DNA indices and have a 
slightly worse prognosis. 
Despite  the  numerous  prognostic  indicators  currently  in  use  or  under  investigation,  it  is 
impossible in an individual case to predict the outcome. 14For this reason, there are continuing searches 
for  better  or  more  refined  biologic  markers  of  prognosis  and  more  effective  treatment  modalities. 
Current  therapeutic  approaches  include  local  and  regional  control  using  combination  of  surgery 
(mastectomy or breast conservation) and postoperative radiation and systemic control using hormonal 
treatment or chemotherapy or both. Newer therapeutic strategies include inhibition (by pharmacologic 
agents or specific antibodies) of membrane-bound growth factor receptors (e.g., HER-2/neu), stromal 
proteases, and angiogenesis. 1,2
  
IMMUNOHISTOCHEMISTRY (IHC)
Immunohistochemistry has over the years evolved into a revolutionary diagnostic tool for the 
pathologist.  The  necessity  for  some special  training  method  can  be  recognized  from the  fact  that 
surgical pathology is a subjective discipline. Despite the presence of various diagnostic criteria, there is 
overlapping among different entities and dissimilarities among the same entity. This when compounded 
with subjective disparity among the pathologists, reproducibility of diagnosis become difficult.40
This prompted the development of special staining technique to stain cells of particular lineage, 
marking the beginning of histochemistry in the mid nineteenth century. Francois Vincent Raspard was 
the first botanist to use immunochemistry.  Advent of aniline dyes revolutionized immunochemistry 
from 1862 to 1929. 41
With the development of immunology, a new method of staining was developed incorporating 
immunologic  techniques.  Here  antibodies  labelled  with  special  stains  are  used  to  identify  special 
antigen in the tissue. The antigen –antibody reaction imparts a particular colour to the cells.
Immunochemistry is an important adjuvant method in histopathologic diagnosis. The origin of 
Immunohistochemistry techniques lies in the pioneering work of Albert Coons, starting in 1941. He 
described his first attempts to label antibodies directly with fluorescent isocyanate. Later the indirect 
technique was introduced by Nakane and Pierce in 1966, in that an unlabeled antibody is followed by 
second  antibody  or  substrate.  Various  stages  of  development  of  Immunohistochemistry  from 
peroxidase  –antiperoxidase  (1970),  Alkaline  phosphatase  labelling  (1971),  Avidin-biotin  technique 
(1977,  1979)  and  to  two  layer  dextrin  polymer  technique  (1993)  carries  both  advantages  and 
disadvantages for each techniques. 5
DETECTION SYSTEM:
Subsequent  to  the  development  of  specific  antibodies  to  the  antigens,  next  step  for  the 
immunochemist was to develop techniques to visualize the antigen-antibody reaction complex.
Two methods employed for this:
1) Direct method
2) Indirect method
DIRECT METHOD:
In this the primary antibody is conjugated directly to the label. Most popular direct conjugates 
are those which are labelled with a fluorochrome, horse radish peroxidase and alkaline phosphatase. 
The  advantage  of  this  method is  that  it  is  simple to  use  as  it  requires  one application  of  reagent 
followed by appropriate chromogen substrate solution. 5
INDIRECT METHOD:
[
The sensitivity of immunochemical stains was significantly improved with the development of 
an indirect technique 55. This is a two step method in which labelled secondary antibody reacts with the 
antigen bound to  primary antibody.  Further  increase in  sensitivity over  the indirect  technique was 
achieved with the introduction of peroxidase enzyme complex. Subsequent development exploited the 
strong affinity of Avidin for Biotin and resulted in Avidin- Biotin Complex method. 5
CURRENT TECHNIQUES:
Enhanced polymer  one  step  staining  method (Epos)  is  a  new direct  technique  reported  by 
Pluzek et al in 1993.42 In this, a large number of primary antibody molecules and peroxidase enzymes 
are attached to a dextran polymer “back bone”. This method is rapid, can be used for frozen sections 
and is sensitive enough to demonstrate small amounts of antigen.
Dextran polymer conjugate –two step visualization system is a new indirect system based on 
dextran  technology employed  in  the  Epos  system.  This  method  offers  greater  sensitivity  than  the 
traditional indirect system. It is less time consuming than the three stage Avidin –Biotin system and 
does not read with endogenous biotin 5.
ANTIGEN RETRIEVAL IN IMMUNOHISTOCHEMISTRY (AR-IHC)
The following technique can retrieve many masked antigen in routinely processed tissue.
1. Proteolytic enzyme digestion.
2. Microwave antigen retrieval. 
3. Pressure cooker antigen retrieval.
4. Microwave and trypsin antigen retrieval.
  PROTEOLYTIC ENZYME DIGESTION:
Pre-treating formalin-fixed, routinely processed paraffin sections with proteolytic enzymes to 
unmask certain antigenic determinants was described by Huang et al (1976).44 Before the advent of heat 
pretreatment,  proteolytic  digestion  was  an  essential  requirement  in  antigen  retrieval.  The  most 
commonly used enzymes are trypsin and protease. Enzyme digestion somehow breaks down formalin 
cross-linking  and  unmasks  the  antigenic  sites.  It  still  has  an  important  place  in  demonstrating 
immunoglobulins and complements in renal biopsies, but it has limited value due to problems like over 
digestion, under digestion and antigen destruction.
MICROWAVE ANTIGEN RETRIEVAL:
This is a relatively new and revolutionary technique. Microwave oven heating retrieves many 
antigens thought previously to be either lost or destroyed by routine histological processing techniques. 
It involves the boiling of cleaned formalin –fixed paraffin sections in various solutions and allows rapid 
and uniform heating. Antibodies and such as the proliferation markers anti-Ki67 and MIB-I which are 
unstable in frozen section work well after heat pre-treatment on paraffin wax sections5.
PRESSURE COOKER ANTIGEN RETREIVAL:
Replacing the microwave oven with the Pressure cooker has proved to have some advantages. 
Microwaving of larger  numbers of slides using bigger  containers does suffer  from inconsistencies. 
Miller et al45 in 1995 compared and proved that pressure–cooking method does not suffer from such 
inconsistencies; also it is less- time consuming.
PIT FALLS OF HEAT PRE-TREATMENT:
Care should be taken not to allow the sections to dry after heating, as this destroys antigenicity. 
Damage of nuclear details is seen in poorly fixed tissue. Fibres and fatty tissues tend to detach from the 
slides while heating. Not all antigens are retrieved by heat pretreatment and also some antigens show 
altered staining pattern with some primary antibodies  eg  PGP9.5.  46 
USES OF IMMUNOHISTTOCHEMISTRY IN BREAST PATHOLOGY 5,43
• Assessment  of  Estrogen  and  Progesterone  status  by  using  specific  antibodies  to  the 
receptor proteins.
• Assessment  of  HER-2/neu  protein  overexpression  by using  specific  antibodies  to  the 
HER-/2 neu protein 
• Distinguishing  in  situ  from invasive  carcinoma  by using  antibodies  to  myoepithelial 
markers (e g. Actins, calponin, smooth muscle myosin heavy chain,  P63) and basement 
membrane proteins (eg type IV collagen, laminin)
• Assessment  of metastatic  lesions  of  possible  breast  origin by using antibodies to  ER, 
GCDFP, CK 7/ CK 20 and other marker.
• Evaluation of spindle cell lesions (metaplastic carcinoma Vs mesenchymal lesions ).
• Distinguishing ductal from lobular in situ carcinoma by using antibodies to E- cadherin.
 HORMONE RECEPTORS
In 1950s Elwood V Jensen  47 identified Estrogen Receptor, further in 1996 Kuiper identified 
Estrogen  receptor  β gene. 48 Estrogen  and  Progesterone  receptors  are  localized  in  the  nuclei  of 
approximately 7% of epithelial cells of normal breast tissue. They are found in higher proportion in the 
lobular than the ductal cells.  48 Shoker at al  49 reported the tendency of contiguous Estrogen receptor 
positive pattern of valuable size in lobular unit. Variation in expression during menstrual period was 
also reported. 50
Estrogen  and  Progesterone  receptors  belong  to  super  family  protein.  They  are  nuclear 
transcription factors that are involved in breast development, growth, differentiation and tumorigenesis 
5,48. Estrogen receptor regulates the expression of other genes such as Progesterone & bcl2  48. Thus 
Progesterone receptor is an indicator for intact Estrogen receptor functional pathway. There are two 
forms of Estrogen receptor referred to as Estrogen receptor alpha & Estrogen receptor beta encoded by 
6p25.1 and 14q respectively.  51 Estrogen receptor alpha is found in endometrium, breast cancer cells, 
ovarian stroma and hypothalamus. Estrogen receptor beta distribution is seen in kidney, brain, bone, 
heart and lungs 48,49.
Walker  D (1999) described that Estrogen receptors  are  regarded as cytoplasmic receptor in 
unliganded state. Since  they are  steroid receptors, they do not require membrane bound receptors for 
their activation. During activation Estrogen receptor rapidly diffuses into the cytoplasm, it migrates 
from cytosol to nucleus, then dimerisation of the receptor occurs and subsequently it binds into HREs 
(Hormone Response Elements). The DNA – receptor complex activates MAPK/P13K pathway and 
induces cell proliferation. Two hypotheses have been proposed for its action. One hypotheses states 
that Estrogen receptor induces transcription activity by alternative RNA splicing of Estrogen receptor 
alpha subunit thereby inducing rapid uncontrolled proliferation and accumulation of genetic mutation. 
The other hypotheses states that it acts by producing by genomic waste. 48,51
Hormone receptors are well established biomarkers in breast carcinoma and their assessment 
helps in predicting the response to endocrine therapy. 52, 53,54 Receptors can be assessed by either Ligand 
Binding  Assay (LBA) on frozen  sections  or  by immunohistochemistry on  paraffin  sections. 23 No 
laboratories offer LBA, but immunohistochemistry method is done worldwide. This assay is found to 
be superior to LBA. 55
PROGESTRONE RECEPTOR :
        Progesterone receptor is an intracellular steroid receptor that specifically binds to progesterone. 
Progesterone receptor is encoded by a single gene PGR 11q22 and regulated by Estrogen receptor.  49 
Estrogen receptor is always necessary to induce Progesterone receptor.  Binding of hormone to the 
receptor induces structural  changes whereby inducing cell  proliferation.  Estrogen and Progesterone 
receptor  share  a  common  structural  and  functional  organization.  WHO  consensus  development 
conference  (1980)  found that  Progesterone  receptor  expression is  a  predictive  marker.  Hence  it  is 
estrogen regulated; most Progesterone receptor positive carcinomas are Estrogen receptor positive also. 
54,56
        Clarks et al57 (1988) demonstrated Progesterone receptor by immunohisto-    chemistry in formalin 
fixed paraffin embedded section. It is seen visually in the same cells which are positive for Estrogen 
receptor. Scoring system is the same as adopted for Estrogen receptor 56
SCORING SYSTEM:
Estrogen  and  Progesterone  receptors  express  nuclear  positivity.  They  are  scored  by  the 
proportion of tumour cells showing positivity and intensity of the reaction. Both are summated to give 
a total score. 
1. H – SCORE SYSTEM:
        Goulding et al58 (1995) used a semiquantitative method. It is based on the proportion of tumour 
cells  showing  different  degree  of  reactivity.  A  score  of  0-3  was  given  based  on  the  following 
expression.
           0- No reaction
           1-Weak reaction 
           2 – Moderate reaction
           3- Strong reaction 
       
Score calculation =   % weakly positive cells x 1 +
% moderately positive cells x 2+
% strongly positive cells x 3 
Total score comes about 0-300.Using H-score the positive score defined           51-300 and for 
negative upto 50 or less. The main disadvantage of this score is that it is time consuming and hence 
impractical for most pathologists.81        
                                                                 
2. QUICK SCORE SYSTEM:
Barnes  et  al59 (1998)  used  another  scoring  method  called  Quick  score .A  score  for  the 
proportion of stained cells and intensity of staining as follows:-
 Intensity of Staining       Proportion of Staining
        
This  comes  to  a  maximum score  of  8.  Score  of  more  than  2  is  considered  as  positive.  71 
Advantage of this score is that it correlates into probability of response to endocrine therapy. 5
3. Allred 60 scoring system followed by Nidal et al 61, Leake et al. 62
   
 The Intensity score, scored as mentioned above and the Proportion score as follows.
0 No positive cells
1 1-25%  of  positive cells
2 26-50%  of  positive cells
3 51-75%  of  positive cells
4 76-100%  of  positive cells
This gives total score about 0-7.The lower cut-off of less than 10% cells is considered to be positive. 61
[
HER-2 /neu RECEPTORS
Her-2/neu  (c-erb  B  -2)  is  an  oncogene  that  encodes  a  transmembrane  glycoprotein  with 
tyrosinekinase activity. The proto-oncogene is encoded with       17q 11.2 –q12. 24 HER-2/neu belongs 
to EGFR family 63 Overexpression in breast carcinoma leads to recurrence and worst prognosis 24,25 It 
can  be  assayed  by  Florescent  In  situ  Hybridization  (FISH)  for  gene  amplification  and 
Immunohistochemical  method  for  protein  over  expression.  In  over  90%  gene  amplification  is 
associated with protein expression. Food and Drug Administration approves two tests, one is Hercep 
test for immunohistochemistry and another is Pathvysion for FISH. 54. When compared to each other 
immunohistochemistry is relatively easy to perform and is less expensive. 63,64
If the immunotest gives 1+ or 2+ it can be confirmed with FISH. Reliability for both the tests 
depends on laboratory experience 54,64
SCORING SYSTEM 65
Staining pattern score HER-2/neu expression
 No  staining  or   membrane  staining  in 
<10% of cells
A faint staining only a part of membrane 
> 10 % of cells 
A weak to moderate complete staining in 
> 10% tumour cells
A  strong  complete  membrane  staining 
> 10% tumour cells
0
1+
2+
3+
Negative
Negative
Weakly positive
Strongly positive
BENEFITS  OF  ESTROGEN  AND  PROGESTERONE  RECEPTOR  ASSESSMENT  IN 
BREAST CARCINOMA :52,53,54
1. Estrogen and Progesterone receptors are weak prognostic factors but strong predictive factors 
for tumor behaviour in breast carcinoma.  
2. Estrogen and Progesterone receptor positive tumours are benefited by hormone therapy in 
50-60% of cases.
3. Estrogen  and Progesterone  receptor  positive  tumours  are  associated  with  reduced  risk  of 
recurrence and mortality.
4. Estrogen and Progesterone receptor negative tumors are not found to 
respond to endocrine therapy.   
MATERIAL AND METHODS
This is a descriptive study of cases of breast carcinoma during the period of May 2007 – June 
2009 in the Department of Pathology, Coimbatore Medical College, Coimbatore. Three hundred and 
sixty eight breast specimens have been received in our department.  during this period, out of this 233 
cases are proven to be malignant.
A  detailed  history  regarding  age,  parity,  socio-economic  status,  family  history,  menstrual 
history, lactational history, and previous biopsy reports are reviewed in all cases. A detailed history 
regarding neo-adjuvant therapy is also noted.
         Patients with unilateral presentation and newly diagnosed patients with no previous neo-adjuvant 
therapy are included in the present study. Patients with bilateral breast malignancies, other associated 
malignancies and those who have undergone neo-adjuvant therapy are excluded from the study.
All the mastectomy specimens received are properly sliced and fixed in 10% formalin for about 
16-18 hours. Detailed gross examination pertaining to  overall size of the specimen, appearance of skin 
with measurements of scars or incisions, appearance of nipple and areola, margins, nodal status are 
carefully noted. The specimens are cut into thin slices and examined .The tumor size, consistency and 
distance from cut margins are noted.
The representative sections are taken from the tumor, nipple, cut margins, deep margins and 
palpable  lymph nodes.  The  tissue slices  are  processed in  various  grades  of  alcohol  and xylol  and 
subsequently embedded in paraffin.  Paraffin sections of 4 µm thickness are subjected to haemotoxylin 
and eosin staining (24).  Histological  assessment of tumor grade is done by  Modified Richardson –
Bloom Scoring system (Annexure -II). Nodal status and margins involvement are recorded in each 
case.
IMMUNOHISTOCHEMICAL ANALYSIS OF HORMONE RECEPTOR:
Immunohistochemical analysis of hormone receptor assay is done in paraffin embedded tissue 
blocks, by using the Supersensitive Polymer HRP system based on non-biotin polymeric technology 
that  makes  use  of  two major  components,  Super  enhancer  and  poly-  HRP reagent.  The  retrieved 
antigen  is   bound  to  primary  antibody  and  then  detected  by  the  addition  of  secondary  antibody 
conjugated with horse radish peroxidase polymer and DAB substrate. The score was calculated after 
adequate color development which can be more readily visualized under a light microscope.  
The step by step procedure is included in Annexure III.
  SCORING SYSTEM:
             Immunohistochemically stained slides are evaluated for the presence of reaction, cellular 
localization (nuclear or cytoplasm), pattern of staining (focal or diffuse) and intensity of reaction in 
individual tumor cells (Strong or weak).  Scoring for Estrogen &Progesterone receptors is  done by 
using Quick score system 59 and for HER-2/neu according to the guideline published by Ellis et al.65
       The statistical analysis is performed with Statistical Package For Social Science(SPSS) software 
version  11.The  Pearson  chi-square  test  is  used  to  compare  the  possible  correlation  studies  like 
Estrogen, Progesterone receptors and HER-2/neu with tumor size, nodal status, histological variants 
and grades. 
The study is conducted after obtaining the ethical approval from the Ethical Review Committee 
of Coimbatore Medical College, Coimbatore.
OBSERVATION AND RESULTS
INCIDENCE OF BREAST TUMORS 
In  the  two  year  study period  from May 2007  –  June  2009,  there  were  27,638  specimens 
received in our department. Of these, breast tumors accounted for 368 cases, the percentage being 
9.4%. 
The number of benign and malignant breast tumors were 135 and 233 respectively. Thus, the 
distribution of benign breast tumors  was 36.65% and that of malignant breast tumors was 63.35%. 
Table  I  shows  the  year  wise  distribution  of  breast  tumors.  During  the  study  period  of 
2007-2008,  benign  tumors  were  46  and  malignant  tumors  were  72.  Subsequently  in  the  year 
2008-2009, benign tumors were 89 and malignant tumors were 161. 
TABLE1. DISTRIBUTION OF BENIGN AND MALIGNANT BREAST TUMORS.
S.No. Year Benign tumors Malignant tumors
1. 2007 – 2008 46 72
2.
2008 – 2009 89 161
Total no of cases 135 233
TABLE 2.   AGE WISE DISTRIBUTION OF THE TUMORS.
Age group Benign tumors Malignant tumors
S.No.
(In years)
1. Less than 20 Yrs
24 -
2. 21-30 Yrs
58(57%) 12
3. 31-40 Yrs
30 32
4. 41-50 Yrs
14 105 (63.33%)
5. 51-60 Yrs
7 46
6. 60 and above
2 38
Total No. of cases
135 233
   
Table 2 shows the distribution of breast tumors according to age. Benign tumors had a peak 
incidence in the age group 21-30 years, where as the malignant tumors had a peak incidence in the age 
group 41-50 years.
TABLE 3. DISTRIBUTION OF HISTOLOGICAL VARIANTS IN BREAST CARCINOMA
S.No. Histological Variants No. of Cases Percentage
1. Invasive Ductal Carcinoma  - NOS type 26 79%
2. Invasive Lobular Carcinoma 1 3%
3. Mucinous Carcinoma 2 6%
4. Papillary  Carcinoma 1 3%
5. Metaplastic Carcinoma 1 3%
6. Neuroendocrine Carcinoma 1 3%
7. Medullary Carcinoma 1 3%
Total No. of  Cases 33 100%
Table 3 shows the distribution of histological variants in breast carcinoma. Among the 33 cases, 
26 (79%) were Invasive Ductal Carcinoma NOS type, 2 (6%) were Mucinous carcinoma and one each 
in other special sub – types including Lobular carcinoma, Papillary carcinoma, Metaplastic carcinoma, 
and Neuroendocrine carcinoma. 
TABLE  4.DISTRIBUTION  OF  HISTOLOGICAL  GRADE  IN  INVASIVE  DUCTAL 
CARCINOMA NOS TYPE
                                         
S.No. Histological Grade No. of Cases Percentage
1. Grade I 1 4%
2. Grade II 23 88.5%
3. Grade III 2 7.6%
Total No. of Cases 26 100%
    Table 4 shows the distribution of histological grading in breast carcinoma according to Modified 
Bloom-Richardson scoring system (Annexure II).Only 26 cases were included for grading, in that 23 
cases (88.4%) were in   grade II, 2 cases (7.6%) were in grade III and one case (4%) in grade I.
TABLE 5.SCORING SYSTEM FOR HORMONAL RECEPTORS
           Of the total 233 cases in the study period, cases were analyzed on the basis of inclusion and 
exclusion  criteria.  Among  these,  33  specimens  were  randomly  selected  for  immunohistochemical 
analysis. All the cases were processed, immunohistochemically analyzed and carefully examined under 
the light microscope. Dark brown colour of the nuclei was interpreted as positive score for Estrogen 
and Progesterone receptor. For scoring Quick score system was adopted. A total score of more than 2 
was considered as positive.
        Dark brown membrane positivity was scored for HER -2/neu. Intensity of staining, percentage of 
cells positivity were included and scored. A score of complete membrane positivity in >10% of the 
tumor cells were considered as positive.
ER, PR, HER-2/neu SCORING TABLE
S.No HPE NO TYPE OF 
CARCINOMA
ER PR
PS IS TS PS IS TS
HER-2
/neu
1 297/08 IDC-NOS GrII  2 0 2 1 1 2 3+
2 553/08 IDC-NOS GrII  5 3 8 5 3 8 2+
3 587/08 IDC-NOS  GrII  1 1 2 1 1 2 3+
4 594/08 IDC-NOS GrII  1 0 2 1 1 1 3+
5 819/08 IDC-NOS GrII  1 1 2 1 1 2 1+
6 836/08 IDC-NOS GrII  1 0 1 2 1 3 3+
7 840/08 IDC-NOS GrII  1 0 1 3 3 6 3+
8 841/08 IDC-NOS GrII  0 1 1 2 2 4 3+
9 1068/08 IDC-NOS GrII  2 1 3 1 1 2 3+
10 1114/08 IDC-NOS GrII  4 2 6 1 3 4 1+
11 1148/08 IDC-NOS GrII  1 0 1 2 1 3 1+
12 1183/08 Mucinous Ca 4 3 7 3 2 5 1+
13 1196/08 IDC-NOS GrII  1 1 2 3 2 5 1+
14 1215/08 Metaplastic Ca 0 1 1 0 1 1 1+
15 1227/08 IDC-NOS GrII  1 0 1 0 1 1 3+
16 1265/08 IDC-NOS GrII  1 0 1 3 2 5 2+
17 1292/08 IDC-NOS GrI 0 0 0 3 2 5 1+
18 1325/08 IDC-NOS GrII  2 1 3 3 3 6 2+
19 1332/08 IDC-NOS GrIII 1 1 2 1 1 2 3+
20 1429/08 IDC-NOS GrII  1 0 1 1 0 1 3+
21 1445/08 IDC-NOS GrII  5 2 7 1 1 2 2+
22 2672/08 IDC-NOS GrII  1 0 1 1 0 1 3+
23 2729/08 IDC-NOS GrII  4 3 7 3 2 5 2+
24 2834/08 IDC-NOS GrII  4 2 6 4 2 6 3+
25 33/09 IDC-NOS GrII  2 2 4 1 1 2 3+
26 34/09 Neuroendocrine 4 3 7 4 3 7 2+
27 82/09 IDC-NOS GrII  1 1 2 1 1 2 3+
28 105/09 IDC-NOS GrII  1 0 2 0 0 0 3+
29 134/09 IDC-NOS GrII  5 3 8 2 1 3 3+
30 157/09 Mucinous Ca 4 3 7 4 2 6 1+
31 834/09 Papillary Ca 3 3 6 4 2 6 1+
32 979/09 Lobular Ca 1 0 1 1 0 1 1+
33 1174/09 Medullary Ca 2 1 3 2 0 2 2+
PS - Proportion Score
IS - Intensity of Staining
TS - Total Score
TABLE  6.  CORRELATION  OF  ESTROGEN  RECEPTOR  WITH 
PROGESTERONE RECEPTOR 
S.No. Group No. of Cases Percentage
1. ER + / PR + 8 24.24%
2. ER - / PR + 6 18.18%
3. ER + / PR - 3 9.10%
4. ER - / PR - 16 48.48%
Total No of cases 33 100%
Table 6. shows correlation between Estrogen receptors and Progesterone receptors. Among the 
33 cases,  8  cases  were  positive for  both estrogen and progesterone receptors,  3  were positive for 
Estrogen  receptor,  6  were  positive  for  progesterone  receptor,  while  16  were  negative  for    both 
receptors.
             Estrogen receptor, progesterone receptor or both were positive in (17cases) 51.52 % where as 
Estrogen receptor, progesterone receptor or both were negative in (16cases) 48.48%
TABLE 7. EXPRESSION OF HER-2/neu IN BREAST CARCINOMA
S.no HER-2/neu expression Total No. of 
cases
Percentage 
%
1. Positive 14
2. Negative 19
33
42.42%
57.58%
        Table 7. shows HER-2/neu overexpression in 33 breast carcinoma patients, among them 14 cases 
(42.42%) were found to be positive, while 19 cases (57.57%) were found to be negative.
TABLE 8. CORRELATION OF TUMOUR SIZE WITH HORMONE        
                                          RECEPTORS.
S.No. Tumor Size Total
ER / PR 
Positive
Percentage
%
1. T1  < 2 cm 3 2 66%
2. T2    2- 5 cm 12 9 75%
3. T3    >5 cm 18 6 33%
Total No. of Cases 33 17
Table  8.  shows  correlation  of  hormone  receptors  with  tumor  size.  Estrogen  receptor  and 
Progesterone receptor positivity was noted in 66% of T1 sized tumors, 75% of T2 sized tumors, and 
33% of T3  sized tumors.  The receptor status was found to be comparatively reduced in larger sized 
tumors as depicted.
The correlation of hormone receptors with tumor size was statistically analyzed and found to be 
significant (p=0.003).
TABLE 9.CORRELATION OF HER-2/neu  WITH TUMOR SIZE
S.NO Tumor size
HER-2/neu 
positive
Total cases
PERCENTAGE 
%
1. <2cm 2 2 100%
2. 2-5cm 8 12 66.66%
3. >5cm 9 19 47.3%
Table 9. shows correlation of HER-2 /neu with tumor size.  HER-2/neu overexpression was 
noted in 100% of T1 sized tumors, 66.66% in T2 sized tumors and 47.3% in T3 sized tumors. There was 
no significant  correlation  between the  tumor size and oncoprotein expression.  This  was  expressed 
consistently in tumors of all size.
TABLE 10. CORRELATION OF RECEPTOR STATUS WITH HISTOLOGICAL GRADING
S.NO
Histological 
grade
Total No. of 
cases
ER/PR 
positive
Percentage
1. Grade I 1 1 100%
2
Grade II 23 14 60.8%
3.
Grade III 2 0 0%
Table12.  shows correlation of hormone receptors  with tumor grade,  Estrogen,  Progesterone 
receptor positivity was seen 100% in grade I tumors, 60% in grade II tumors and none in grade III 
tumors. High histological grade tumors showed low expression of receptors.
TABLE 11.CORRELATION OF HER-2/neu WITH HISTOLOGICAL GRADING
S.No Histological grade HER-2/neu positive Percentage
1. Grade I(1case) 0 0
2. Grade II(23 cases) 13 56.5%
Grade III(2cases) 2 100%
3.
Table  13.  shows  correlation  of  HER-2/neu  with  histological  grade.   It  was  found  that 
HER-2/neu overexpression was not seen in grade I tumors, where as it was expressed in 56.5% of 
grade II tumors and 100% of    grade III tumors.
       Statistical analysis was done and found to be significant (p=0.001).
TABLE 12.CORRELATION OF RECEPTOR STATUS WITH NODAL STATUS
S.NO Nodal metastasis ER/PR Positive Percentage
1. Present
(15 cases)
5 Cases 33.3%
2. Negative
(18 cases)
10 Cases 55.5%
Table10. shows correlation of hormone receptors with nodal status. Out of 33 patients 15 had 
nodal metastasis, among whom 5 showed receptor positivity. Out of 18 nodal negative patients, the 
receptor status was positive in 10 patients. This explains higher receptor expression in nodal negative 
patients.
Statistical analysis was done and found to be significant (p=0.001) 
TABLE 13.CORRELATION OF HER-2/neu  WITH NODAL STATUS
S.NO Nodal metastasis HER-2/neu Positive Percentage
1.
Present (15 cases) 10 cases 66.6%
2.
Negative (18 cases) 2 cases 11.1%
Table11. shows correlation of HER-2/neu with nodal status. Out of 33 patients, HER-2/neu 
overexpression was seen in 66.66% of nodal positive as opposed to 11.1% of nodal negative patients. 
Statistical analysis was done and found to be significant (p=0.001) 
TABLE 14.CORRELATION OF RECEPTORS WITH ONCO PROTEIN EXPRESSION
ER/PR Status
HER-2 / neu
Positive Negative
Total No. of 
Cases
Positive
2 15 17
Negative
12 4 16
Total No. of
Cases
14 19 33
Table14.  shows  an  inverse  relationship  of   Estrogen  ,  Progesterone  receptor  status   with 
HER-2 / neu status.
Statistical  analysis  was  performed  with  the  SPSS  version  11.  and  found  to  be  significant 
(p=0.001).
DISCUSSION 
Incidence and Age of Occurrence:
In  the  Indian  scenario,  breast  carcinoma and cervical  carcinoma account  for  about  60% of 
malignancies in women, the incidence of breast cancer alone being 10.4%  4.A study conducted by 
WHO  7 indicates that  Chennai  recorded the highest  number of cases  in India,  the incidence being 
26/1,00,000 women. The age of occurrence is between 41-50years. 7
 
          In concurrance with the above mentioned studies, the current study also revealed that the 
distribution of disease was about 9.4%. The age of peak occurrence of malignancy was 41–50 years 
group. 
Table 15.  Comparative analysis of Distribution  of Histological variants of Breast carcinoma.
Histological types Dixon JM etal Omar  Hameed Current study
I DC – NOS type 79% >70% 79%
Lobular carcinoma 10% 5 – 15% 3%
Mucinous  carcinoma 2% 1-5% 6%
Medullary carcinoma 2% 1-7% 3%
Papillary carcinoma 1% 2% 3%
Solid neuroendocrine ca < 1% rare 3%
Metaplastic carcinoma _ 2-5% 3%
 
     Table15. shows the comparative  analysis  of the distribution of  histological  variants  of  breast 
carcinoma. The incidence encountered by Dixon et al22 and Omar Hameed et al  66 were comparable 
with  present  study.  The  most  common histological  type  in  accordance  with  the  other  results  was 
Invasive ductal carcinoma – NOS type accounting for 79%.
 The identifiable histological variants are as follows:
1. Invasive ductal carcinoma –NOS type:
This  comprises  the  largest  group  of  malignant  tumors  accounting  to  65-80%  of  breast 
carcinoma 14,15.  Our study shows 79% distribution.
Grossly the tumor size varied from 2.7cm to 18.5cm. Cut section of most of the tumor showed 
gray white, ill-defined tumor mass, firm to hard in consistency. (Fig.1) Occasionally tumor showed 
areas of hemorrhage and necrosis.  Microscopically the neoplastic cells were arranged in diffuse sheets, 
nests and cords along with glandular and tubular differentiation.  In few cases comedo - pattern of 
necrosis was seen. (Fig.2)   About Fifty percent of the cases (15/33) showed nodal metastasis. Most of 
the tumors were found to be in histological grade II. Resected margin involvement  was seen in two 
patients  and  was  confirmed  by  microscopic  examination.  None  of  these  patients  had  either  skin 
involvement or Paget’s disease.
2. Invasive Lobular carcinoma:
Foot and Stewart  20 recorded an incidence of 4.9 -12% in post menopausal age group. In the 
present study this variant represented  3% of occurrence.  But in contrast to Foot and Stewart 20   the 
age of occurrence was 35 years. Grossly the tumor was gray white, firm  measuring  6cms in diameter 
(Fig.3). Microscopically “Indian file” pattern was noted (Fig.4). The cells were small to medium sized 
with uniform, hyperchromatic nuclei,  and mild nuclear pleomorphism.  Microscopically,  metastasis 
was found in 23 lymph nodes.
3. Mucinous carcinoma:
 In Omar Hameed et al66 study incidence of Mucinous carcinomas was 5-15% and the mean age 
of occurrence was 58-68 years. The present study data represents 6% of distribution and the age of 
occurrence was 63years.  This is parallel with above mentioned study.
Grossly the tumor mass was about 6cm -10cm, well circumscribed with gelatinous appearance.
(Fig.5)  On cut section soft, gel like material was noted.  Microscopically clusters of bland appearing 
epithelial cells with abundant extracellular mucin were noted (Fig.6).
4. Medullary Carcinoma:
Omar  Hameed66  reported the  incidence of  Medullary carcinoma as  1-7%, but  Dixon et  al22 
showed  relatively  low  incidence  of  this  type  approximately  2%.  Current  data  represents  6%  of 
distribution which is in comparable with Omar Hameed .
Grossly the tumor was about 5.5cm, well circumscribed, gray white, soft in consistency with foci of 
necrosis  and  hemorrhage  (Fig.7).  The  WHO  book  describes  the  classical  microscopic  finding  as 
follows (Fig.8). 17
1) Syncytial growth pattern in >75% of the tumor. 
2) Absence of glandular structure
3) Diffuse lymphoplasmacytic infiltration.
4) Microscopic circumscription:  in that edge of the tumor should have a smooth rounded contour.
5) Poorly differentiated nuclear grade with high mitotic index. 
5. Papillary carcinoma:
This tumor type accounts for 2% of all invasive carcinomas. It is most frequently encountered 
in post menopausal women.22,66  In  the current study the age of occurrence was 68 years and represents 
3% of distribution. This is in parallel with the study of Dixon et al. 22
Grossly the tumor measured about 3cm, appears  well circumscribed, pale white in color with 
granular  appearance  and   was  easily  detached  from  the  surrounding  tissue  (Fig.9).Microscopic 
pathology  revealed  predominantly  papillary  structure  with  fibro-vascular  core  and  lined  by 
multilayered epithelial cells. In high power (40X) examination the absence of myoepithelial cells was 
confirmed. Invasion of papillary structure into the surrounding stroma with stromal reaction was noted 
(Fig.10).
6. Metaplastic carcinoma:
         
A very rare entity was included in our study. This represents 3% of distribution.  Grossly the 
tumor was an ill defined gray white mass, firm to hard in consistency and was measuring about 19cms 
(Fig.11).  Microscopically chondroid  differentiation was noted predominantly.  There  was an  abrupt 
transition  from  intraductal  carcinoma  to  metaplastic  component.  Focal  areas  show  spindle  cell 
morphology (fig.12).
7. Neuroendocrine carcinoma:
In Omar Hameed et al66 study incidence of Neuroendocrine carcinoma was    2-5%. The present 
study data  showed 3% distribution,  which is  comparable with the above study.  Grossly the tumor 
showed an ill defined, gray-white friable mass measuring about 2 cm (Fig.13).Microscopically, nested 
appearance of cell groups surrounded by a collagenous stroma was noted. The cells were composed of 
uniform small round hyperchromatic nuclei with very minimal pleomorphism.  Mitotic figures were 
increased.  
Hormone Receptor status in breast carcinomas:
 Estrogen, Progesterone receptor positive tumors tend to have a significantly longer disease free 
survival than with receptor negative tumors.39, 52, 53, 54
Earlier in 1975 Rosen et al  18 attempted to correlate Estrogen, Progesterone receptors status 
along  with  various  histological  types  of  breast  carcinoma.   In  his  study  Estrogen,  progesterone 
receptors were positive in 70-80% of the tumors and HER-2/ neu expression was  present in 15-20% of 
the tumors.
Wilbur  D  et  al  67 (1993)  studied  about  hormone  receptor  status  in  30  patients  by 
immunohistochemical  method  on  paraffin  embedded  blocks.   He  described  Estrogen  receptors 
positivity in 73% (22/30), Progesterone receptors positivity in 63% (19/30), and HER-2/neu expression 
in 37% (11/30).
         Lici et al (2003) 68 have documented the incidence of invasive carcinoma by hormone receptor 
status  from 1992 to  1998 in  a  population based study.  He found that  hormone receptor  positivity 
increased from 75.4% to 77.5% in United States with a rise in prevalence over the years.
The  number  of  studies  performed  on  this  topic  is  much  less  in  Asian  communities  when 
compared with western world. Desai et al 69 (2000) documented the Estrogen, Progesterone receptors 
status of breast carcinoma in India. The procedure was done by immunohistochemical method. Out of 
798 tumors, 32.6% were Estrogen receptor positive and 46.1% were Progesterone receptor positive. He 
obtained a high incidence of steroid receptors non-reactivity in breast carcinoma patients in India. 
         Col.V. Dutta et al  70 (2008) conducted a study in Armed Forces Medical College, Pune. The 
author analyzed Hormone receptors and HER-2/neu  expression in breast carcinoma. In total of 75 
tumors, 33% (25/75) cases expressed Estrogen receptor, Progesterone receptor or both where as 67% 
(50/75) were found to be both the receptor negative. HER-2/neu overexpression was seen in 58 %
( 43/75) of tumors. This study reveals that receptor negativity is higher in this subset of tumors when 
compared with western communities.  
   
Lakmini K.B Mudduwa 71 (2009) studied Hormone receptor status of breast carcinoma by using 
Quick score method. She has reviewed 151 cases and documented prevalence of Estrogen receptor 
positivity in 45.7%, Progesterone receptor positivity in 48.3% and both receptors negativity in 54.3%. 
According to this study HER-2/neu overexpression was seen in 19.1% (26/136) cases. 
          Tanuja Shet et al 72  (2009) studied hormone receptors expression in the last 8 years from 1999 to 
2006 in a cancer referral center in India. A total of 11,780 cases were reviewed. The percentage of 
hormone receptor expression varied from 52% to 57%.
Vikash Kumar et al  73 (2007) studied HER-2/neu oncogene overexpression which was much 
higher among Indian breast cancer patients 46.3% in comparison to 25-30% in Western literature.
 
            In the present study Estrogen, Progesterone receptor or both were positive in 51.6% cases and 
both receptors were negative in 48.4% cases (Tab.6). HER-2/neu overexpression was in 42.7% cases 
(Tab.7).  Hence  this  study is  comparable  with  the  studies  conducted in  the  Asian countries.  There 
appears  to  be  a  minimal  variation  in  receptor  expression;  technically  this  could  be  explained  by 
differences in technique of evaluation and inter laboratory variations. 
Estrogen, Progesterone receptor and HER-2/neu status in Histological      variants:
Rosen  PP et al 1975  18 found that Mucinous carcinomas, Papillary carcinomas are Estrogen, 
Progesterone receptors positive whereas Metaplastic carcinoma and Medullary carcinoma tend to be 
both receptor negative. The author has found that a small set of Invasive ductal carcinoma-NOS type 
and Lobular carcinomas showed   receptor negativity.
Desai et al  69 (2000) described that Invasive lobular carcinoma, Mucinous carcinoma, mixed 
tumors  were  Estrogen,  Progesterone   receptor  positive,  where  as  high  grade  infiltrating  ductal 
carcinomas, Medullary carcinomas, in situ comedo-ductal carcinomas  tended  to be  receptor negative.
Diab SG et al  26 has studied the  tumor characteristics and clinical outcome of Tubular and 
Mucinous  breast carcinomas, found Estrogen receptor positivity in 92% cases, Progesterone receptor 
positivity in 68% of cases and HER-2/neu expression in less than 5% of tumors. Similar results were 
also noted in studies conducted by Shousha S, et al 83 (1989).
Reiner et al (1988)  74   found that Papillary carcinomas are  100% Estrogen receptor positive, 
80% Progesterone  receptor  positive  and they tended to have a  HER-2/neu negativity . 
         Rosen  et  al  38  (1995)  studied  HER-2/neu  expression  in  nodal  negative  patients.  He has 
documented low incidence of oncogene expression in Papillary carcinomas.
        In 1991 Soomro S et al  75 studied about oncogene expression in different histological types of 
invasive breast carcinomas and quoted low expression in Neuroendocrine carcinomas.  
 Immunohistochemical studies by LeeAK31 showed Neuroendocrine marker positivity in 82% of 
the cases. However 67% showed Estrogen receptor positivity and 56% exhibited  Progesterone receptor 
positivity. 30, 32 HER-2/neu  over expression was found to be negative. 32 
The present study shows Estrogen, Progesterone receptor positivity and HER-2/neu negativity 
in  Mucinous  carcinomas  (Fig.21),  Papillary  carcinoma  (Fig.23)  and  Neuroendocrine  carcinoma 
(Fig.22). This is in correlation with above mentioned studies.
A study by Oberman HA et al  36  (1987) showed that Metaplastic carcinomas were Hormone 
receptor and oncoprotein negative. (Triple negative) 14, 17
Horsfall et al  29  (1986) conducted study on relationship between ploidy and steroid receptors. 
The author found that Medullary carcinoma is a high nuclear grade tumor with receptor negativity.
            A study by Rosen PP et al 38 (1995) and Soomro S.et al 76 (1991) showed a low incidence of 
HER-2/neu receptor overexpression in Medullary and Metaplastic carcinoma.
The present study also denoted Triple negativity in both Medullary and Metaplastic carcinomas 
(Fig.24).
                Kuenen–Boumeester V et al (1992)76 studied immunohistochemistry of Androgen receptor in 
relation to Estrogen and  Progesterone receptors. He has reported that a small set of lobular carcinomas 
tend to express both receptors negativity and Androgen receptor positivity.
            A study by Rosen PP et al  38 (1995) showed Estrogen receptor positivity in 87.55% and, 
Progesterone receptor positivity in 75% of the tumours in Invasive lobular carcinomas. A small subset 
expressed both receptor negativity and invariably Androgen receptor positivity.
            Riva et al  77 (2005) studied immunhistochemical analysis of Androgen receptor in breast 
carcinoma and showed frequent expression in Lobular carcinomas along with Estrogen, Progesterone 
receptors negativity.
          In correlation with the above reference the Invasive lobular carcinoma in the present study also 
expressed both receptors and HER-2/neu negativity.  Clinicopathologically this can be explained by 
aggressive nature of the tumor with higher nodal metastases.
Table.16 Correlation of Age and Receptors expression.
Age group Total no of cases ER/PR positive
31-40 6 3
41-50 11 3
51-60 9 7
61-70 5 4
> 70 yrs 2 -
            Col.V. Dutta et al 70 (2008) studied about Estrogen, Progesterone receptor expression with the 
age. Out of 75 cases 35% of cases were in 51-60 years age group. The results showed that receptor 
positivity increases with age.  Young patients tend to have a high level of circulating estrogen and 
correspondingly low expression of receptors.
                Nidal M Almasri et al  61 (2005) has reviewed 91 specimens  of breast tumors during the 
period of 1995-1999. The author has found significant receptor expression in 58% patients older than 
50 years.
         The present study shows receptor status positivity of 77.77% in patients older than 50years age 
group. The Increased immunoreactivity with advancing age is parallel to above mentioned studies. 
Estrogen, Progesterone receptor, HER-2/neu with other variables:
Rosen PP et al 38 (1995) in his study correlated Estrogen, Progesterone receptor positivity with 
tumor size and histological grade. He concluded Estrogen, Progesterone receptor expressed more in 
low grade tumors and tumors of lesser diameter. HER-2/ neu overexpression was more among the 
nodal positive patients and tumors more than 2cm in diameter. 15 
J.Buon et  al  78 found HER-2/neu receptor overexpression in higher grade tumors.  Hormone 
receptor positivity was seen 100% in grade I tumors, 76.30% in grade II tumors, and 41.18% in grade 
III tumors. Their positivity tends to have an inverse relationship with tumor grade.
   S.Goyle et al 79 (2008) conducted a retrospective study in India. He has reviewed 131 patients 
and  found  that  receptor  and  oncoprotein  expression  does  not  necessarily  correlate  with  advanced 
tumors in our population.
                In contrast with S.Goyle et al  79 (2008) the present study showed (Tab.12) Estrogen, 
Progesterone receptor positivity of 100% in grade I,  60.8% in grade II,  none in grade III  tumors. 
HER-2 /neu overexpression showed 100% in grade III, 56.5% in grade II, none in grade I tumors. This 
explains the overexpression of oncoprotein with higher histological grade tumors. Thus, it reflected a 
direct relationship with higher nuclear grade, which was comparable with J.Buon et al 78 & Rosen PP et 
al.38
                Current study shows correlation of hormone receptors and HER-2/neu  with tumor size. For  
practical purpose the tumors are categorized into three, T1- < 2cm, T2=2-5cm, T3 = > 5 cm. As depicted 
in (Tab.8) 66% of T1, 75% of T2 and 33% of T3 tumor showed receptor positivity. This explains that 
receptor positivity has an inverse relationship with tumor size.
HER-2/neu overexpression showed no expression in T1, 66.6% in T2 and 48% in T3 tumors. 
(Tab.9). This explains the higher expression among the tumors of more than 2 cm size.
Correlation with nodal status:
           Col.V. Dutta et  al  70 (2008) studied a strong correlation between HER-2/neu and nodal 
metastases. He has reported that 70% of nodal positive tumors overexpressed HER-2/neu protein.
          H.J. Huang et al 80 conducted a study in 1362 women with primary breast tumor. He found that 
Estrogen receptor positivity was less in nodal positive tumors.
In present study out of 33 patients 15 cases showed metastasis while 18 cases did not. Receptor 
positivity  was  found  to  be  higher  among  the  nodal  metastasis  negative  patients  55.55% (10/18). 
HER-2/neu overexpression was seen in 66.66% of nodal positive cases than the nodal negative patients 
which was 11.1 %.
Correlation of Estrogen, Progesterone receptor with HER-2/neu:
   H.J. Huang et al 80 conducted a study in 1362 women with primary breast tumor. The author 
has found an inverse relationship with receptor and oncoprotein expression. This can be explained by 
cross-linkage between the two pathways of tumor growth.
The present study (Tab.14) showed an inverse relationship between these hormone receptors 
and oncoprotein expression and therefore is comparable with above mentioned studies.
              Francis G et al 81(2006) in a study of 591 tumors concluded that  more than 20% of HER-2/neu 
positive tumors showed moderate or strong staining for Estrogen receptors.
 
Bhargava R et al  82 (2009) has reviewed   205 cases and concluded that 15% (32/205) were 
triple negative, 4% (8/205) were positive for Estrogen receptor  and   HER-2/neu  hybrid expression.
In  correlation  with  these  studies  the  present  study (Tab.14)  showed two cases  of  Estrogen 
receptor- HER-2/neu positivity. Apart from Metaplastic carcinoma and Medullary carcinoma, one case 
was triple negative. There is no plausible explanation for this kind of receptor expression.
SUMMARY AND CONCLUSION
• The incidence of  breast carcinoma in  patients attending Coimbatore Medical   
College hospital for the year 2007-2009 was 9.4%.
• The distribution of benign breast lesions was 36.65% and that of   malignant 
breast  tumor was 63.35%.
• The benign lesions had a peak occurrence in the age group 21 to 30 years, whereas malignant 
tumors had a peak in the age group 41 to 50 years.
• Among the various histological variants in breast carcinoma, Invasive Ductal  
carcinoma – NOS type constituted 79% of cases.
• Estrogen, Progesterone receptor positivity and HER-2/neu negativity in Mucinous  carcinomas, 
Papillary carcinoma and Neuroendocrine carcinoma.
• Triple negativity in Medullary, Metaplastic carcinomas and Invasive lobular     
carcinoma.
• Regarding the histological grade of breast carcinoma, Grade II tumors were       
     common accounting for 88.5 %.
• Estrogen, Progesterone receptor or both was found in 51.52% while 48.48% were  receptor 
negative.
• HER-2 /neu overexpression was found in 43.43% of tumors and it was negative in 57.57% 
tumors.
• Out  of  the  total  33cases,  18  cases  were  T3   tumors  of  more  than  5cms 
in diameter.
• Larger  the  tumor  size  lesser  the  expression  of  hormone  receptor,  whereas  smaller  one 
expressed more receptor positivity. This inverse correlation was    
statistically significant (P=0.003)
• HER-2/neu overexpression was found in tumors of all size. However, there was no significant 
correlation between the tumor size and HER-2/neu.
• Among 33 cases, nodal metastasis were found in 15 cases and negative in 18      cases.
• Among the 18 nodal negative patients Estrogen, Progesterone receptor were 
positive in 10 cases. Thus, there is higher receptor expression in nodal negative patients. Which 
was found to a have significant correlation  (P=0.001).
• HER-2/neu overexpression was observed in 66.66% of nodal positive patients. 
Which statistically significant (P=0.001).
• Higher the histological grade of breast carcinoma, lower the receptor positivity. None of the 
grade III tumors expressed receptor positivity.
• Higher the histological grade of breast carcinoma, greater the HER-2/neu      
overexpression. Which was found to have  a significant correlation .(P=0.001).
• Higher  the  Estrogen,  Progesterone  receptor  positivity,  lower  was  the         HER-2/neu 
overexpression. Thus, there was an inverse relation between the receptor and HER-2/neu. which 
was found to be  statistically significant (P=0.001).
• Receptor  negativity  is  higher  in  this  subset  of  tumors  when  compared  with  western 
communities.  
CONCLUSION
Estrogen,  Progesterone  receptor  positive  tumors  are  common  in  post  menopausal  women, 
tumors  of  more  than  2cm size,  Histological  grade  I  and  in  nodal  negative  patients.  Oncoprotein 
overexpression is common among the tumors of more than 2cm size, grade III tumors  and in nodal 
positive patients.  When compared with western world Estrogen, Progesterone receptor positive tumors 
are found to be low, while HER-2/neu overexpression is high in this study group. Hormone receptor 
and oncoprotein expression has an inverse correlation with each other.
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  PROFORMA
Serial No. : Name :
HPE No. : Age :
IP No. : Sex :
Clinical diagnosis :
Breast : Right / Left
Specimen : Excisional (Lumpectomy / Mastectomy )
Macroscopic Examination :
Specimen Size :
Skin and Nipple :
Tumor Size :
Tumor margins : Circumscribed / Infiltrative
Posterior margin :
Lymphnode :
Number :
Size :
C/S :
Histological type of lesion :
Skin : Free / Involved
Nipple : Free / Involved
Muscle : Free / Involved
                 
LYMPHNODES
Total Number :
No.of nodes involved :
Other Findings :
Receptor Study :
ER Status:
Proportion Score :
Intensity Score :
Total Score :
PR Status:
Proportion Score :
Intensity Score :
Total Score :
HER – 2/ neu Status :
Weak :
Moderate                  :
Strong Positive                   :
